Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • Guaranteed Paid Placement
  • SocialBoost
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • SocialBoost
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Alzheimer's Drug Discovery Foundation Releases 2021 Clinical Trials Report in Conjunction with 14th Annual CTAD Conference

Findings Highlight Wide Range of Drugs Being Tested to Slow or Even Stop Alzheimer's Progression

(PRNewsfoto/ADDF)

News provided by

Alzheimer's Drug Discovery Foundation

Nov 03, 2021, 14:57 ET

Share this article

Share toX

Share this article

Share toX

NEW YORK, Nov. 3, 2021 /PRNewswire/ -- A more robust pipeline of novel targets spanning all clinical trial phases and an ongoing focus on therapeutics driven by the biology of aging offers new hope for treating Alzheimer's disease, and slowing or stopping its progression, according to the Alzheimer's Drug Discovery Foundation (ADDF). Today, the ADDF announced that it will issue its 2021 Clinical Trials Report (embargoed for Tuesday, November 9, 2021), an analysis of 118 Alzheimer's clinical trials, in conjunction with the 14th Annual Clinical Trials on Alzheimer's Disease Conference (CTAD) in Boston, November 9-12, 2021.

As shown in the report, today's pipeline goes well beyond the once traditional focus on removing toxic build-up of amyloid and tau proteins in the brain. "This report underscores the increased diversity and robustness of the Alzheimer's pipeline, with the majority of the trials exploring novel pathways targeting the many underlying causes of Alzheimer's that go awry during the aging process," says Dr. Howard Fillit, Founding Executive Director and Chief Science Officer of the ADDF, which has long advocated a scientific strategy based on the biology of aging as an effective approach to prevent and treat Alzheimer's disease. "This is an incredibly exciting time in Alzheimer's research, moving us toward the ability to have precision combination therapies, just like those used to treat many cancers today."

Of the 118 disease-modifying trials, three in four (77%) focus on targets other than beta-amyloid or tau, like brain inflammation, breakdown of neurons and electrical signaling pathways, and inefficiencies in how the brain uses energy. The majority are in phase 2 (60%), when a drug is further evaluated for safety and tested for efficacy in larger numbers of people. There is also an increased emphasis in the pipeline on repurposing existing drugs for use in Alzheimer's patients. Nearly 35% of today's Alzheimer's clinical trials are studying drugs that already have FDA approval for other diseases, which speeds up research and cuts costs because their safety in patients is already established.

Alzheimer's disease affects 55 million people globally, with 6 million in the U.S. alone, and is among the top 10 causes of death.

"The holy grail for Alzheimer's disease is new methods of prevention, diagnosis, and treatments to slow the disease's progression, and allow patients to better retain their cognitive function and quality of life. We believe research into previously unexplored pathways will get us there," says Dr. Fillit, noting that Bill Gates, who partnered with the ADDF on its Diagnostics Accelerator shared this optimism in a recent Gates Notes piece. "Many new advances in the field are due to the development of biomarkers, which play an essential role in allowing researchers to enroll the right patients in clinical trials and to monitor how the drugs are working," adds Dr. Fillit.

The ADDF funds one of the largest and most diverse clinical trial portfolios with over 30 active trials that explore the many complex and underlying causes of Alzheimer's, including changes in proteins, chronic inflammation, vascular disease, loss of synapses, and changes in genes. As part of its mission to rapidly accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, the ADDF regularly reviews the Alzheimer's research landscape to better understand current research and devise the best strategies for investing ADDF resources to speed success.

The ADDF's Clinical Trials Report is based on a review of more than 200 ongoing Alzheimer's clinical trials. In addition to the 118 disease-modifying treatments that are the cornerstone of the research pipeline, the report provides details on nearly 100 more trials testing treatments that target behavioral symptoms connected to Alzheimer's, such as anxiety and agitation, trials looking at ways to prevent Alzheimer's from the beginning, and trials validating new biomarkers that can be used on the frontlines to improve early detection and diagnosis of the disease.

Nine ADDF-Funded Investigators to Present at CTAD

The range of topics covered by nine ADDF-funded researchers at CTAD reflects the ADDF's 360-degree commitment to tackling Alzheimer's disease, notes Dr. Fillit. They include the following:

Wednesday, November 10th

  • (9:35am EST) OC4 - Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): Methodology for a Randomized, Double-Blind, Placebo-Controlled Phase II Trial
  • (9:50am EST) ROUNDTABLE 3: Digital Therapeutics for Mild Cognitive Impairment: New Pathway to Treatment
  • (3:45pm EST) ROC9 - Performance of the PrecivityAD™ blood test in detection of brain amyloidosis in cognitively normal and cognitively impaired individuals
  • (4:30pm EST) SYMPOSIUM 3: Bringing Repurposed Drugs to Market: Challenges and Opportunities from Research to Commercialization (Moderated by Dr. Fillit)

Thursday, November 11th

  • (10:35am EST) LB6 - LM11A-31 small molecule p75 receptor modulator – phase 2a randomized placebo-controlled safety and exploratory endpoint trial in mild-moderate Alzheimer's disease
  • (2:05pm EST) OC18 - HOPE4MCI Trial: First Trial Targeting Reduction of Hippocampal Overactivity to Treat Mild Cognitive Impairment due to Alzheimer's Disease with AGB101
  • (4:10pm EST) ROUNDTABLE 7: Value-Generating Exploratory Trials in Neurodegenerative Dementias (Moderated by Dr. Fillit)

To view the full program for the 14th Annual CTAD Conference, visit the conference website.

About the Alzheimer's Drug Discovery Foundation
Founded in 1988 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's' employing a venture philanthropy model to support research in academic and the biotech industry. Through the generosity of its donors, the ADDF has awarded more than $168 million to fund over 650 Alzheimer's drug discovery and biomarker programs and clinical trials in 19 countries. To learn more, please visit: http://www.alzdiscovery.org.

SOURCE Alzheimer's Drug Discovery Foundation

Related Links

www.alzdiscovery.org

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

FDA Approval of Leqembi Subcutaneous Formulation Charts Path to Combination Therapies for Alzheimer's Disease

FDA Approval of Leqembi Subcutaneous Formulation Charts Path to Combination Therapies for Alzheimer's Disease

The U.S. Food and Drug Administration (FDA) today announced its approval of a subcutaneous formulation of Leqembi (lecanemab), branded as Leqembi...

New Alzheimer's Clinical Guidelines Move Towards Replacing More Invasive Tools with Blood Tests; Pressing Need for Further Guidance Remains

New Alzheimer's Clinical Guidelines Move Towards Replacing More Invasive Tools with Blood Tests; Pressing Need for Further Guidance Remains

Expanding the use of Alzheimer's blood tests is crucial to usher in a new era of precision medicine and bring Alzheimer's disease into mainstream...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Infection Control

Infection Control

Mental Health

Mental Health

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.